Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell Sage Group (SGE) by Canaccord Genuity
- Buy Michelmersh Brick Holdings (MBH) by Canaccord Genuity
- Buy B&M European Value Retail S.A. (DI) (BME) by Canaccord Genuity
- Neutral Anglo American (AAL) by JP Morgan
- Underweight Antofagasta (ANTO) by JP Morgan
- Overweight Fresnillo (FRES) by JP Morgan
- Overweight Hochschild Mining (HOC) by JP Morgan
- Outperform Breedon Group (BREE) by RBC Capital
- Buy LBG Media (LBG) by Shore Capital
- Buy DFS Furniture (DFS) by Jefferies
- Buy Balfour Beatty (BBY) by Deutsche Bank
- Buy Helios Underwriting (HUW) by Deutsche Bank
- Buy Jet2 (JET2) by Deutsche Bank
- Hold Sage Group (SGE) by Deutsche Bank
- Buy SSE (SSE) by HSBC
- Hold WPP (WPP) by HSBC
- Buy Flutter Entertainment (DI) (FLTR) by Goldman Sachs
- Buy Sage Group (SGE) by Citi
- Buy B&M European Value Retail S.A. (DI) (BME) by Citi
- Buy Clarkson (CKN) by Berenberg
C4X Discovery Holdings (C4XD) Share Price
Health Care Sector
NOTE: This is based on 2 open tips for C4X Discovery Holdings (C4XD)
| Latest Bid : 10.00p | Latest Ask : 10.80p |
| High Today : 10.20p | Low Today : 8.30p |
| This Years High : 21.45p | This Years Low : 7.80p |
| Volume : 3,230,441 | MKT Cap : £27.22M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
C4X Discovery Holdings (C4XD) Overview
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.C4X Discovery Holdings (C4XD) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Shore Capital | Premium Only | 2023-12-14 14:30:00 14/12/2023 | 11.11% |
| Buy | Panmure Gordon | Premium Only | 2017-02-21 10:00:00 21/02/2017 | -87.02% |
C4X Discovery Holdings (C4XD) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 10.00p | Latest Ask : 10.80p |
| High Today : 10.20p | Low Today : 8.30p |
| This Years High : 21.45p | This Years Low : 7.80p |
| Volume : 3,230,441 | MKT Cap : £27.22M |
C4X Discovery Holdings Overview
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest C4X Discovery Holdings Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Shore Capital | Premium Only | 2023-12-14 14:30:00 14/12/2023 | 11.11% |
| Buy | Panmure Gordon | Premium Only | 2017-02-21 10:00:00 21/02/2017 | -87.02% |